American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 7(67), 2023
DOI: 10.1128/aac.00266-23
Full text: Download
The emergence of the Omicron variant of SARS-CoV-2 represented a challenge to the treatment of COVID-19 using monoclonal antibodies. Only Sotrovimab maintained partial activity, allowing it to be used in high-risk patients infected with the Omicron variant.